Web Desc
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology
Organizer(s): Robert D. Schreiber, James P. Allison, Philip D. Greenberg and Glenn Dranoff
Date: March 19 - 23, 2017
Location: Fairmont Chateau Whistler, Whistler, BC, Canada
Sponsored by Astellas Pharma Inc., AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, Cell Signaling Technology, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. ,Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche, Sangamo Therapeutics, Inc., Takeda Pharmaceutical Company Limited and TESARO, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
The fields of cancer immunology and immunotherapy continue to make great strides in providing both a comprehensive understanding of the basic mechanisms underlying tumor-immune system interactions and applying this knowledge to the development of effective immune-based cancer therapies. This Keystone Symposia meeting is organized to highlight recent insights into the complex roles of immune components and pathways in controlling or alternatively promoting cancer and to showcase recent uses of cancer vaccines, checkpoint blocking strategies, adoptive cell therapies and cellular engineering approaches, either as mono- or combinatorial therapies, that have resulted in durable, effective and safe therapeutic responses to an increasing number of cancer patients. Part of the meeting will also focus on new, developing technologies that are likely to expand our capacity to monitor the effects of cancer immunotherapy with a precision, refinement and at a level that has not been possible in the past.
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Astellas Pharma Inc.AstraZenecaBill & Melinda Gates FoundationBioLegend, Inc.Bristol-Myers Squibb CompanyCell ResearchCell Signaling Technology, Inc.Genentech, Inc.Genmab A/SImmunoGen, Inc.Incyte CorporationJuno TherapeuticsMerck & Co., Inc.Mersana TherapeuticsMorphoSys AGOncoMed Pharmaceuticals, Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.RocheSangamo Therapeutics, Inc.Takeda Pharmaceutical Company LimitedTESARO, Inc.
We gratefully acknowledge additional support for this conference from:
Adipogen InternationalAmerican Association for Cancer Research (AACR)Cellcion, LLCInSphero Inc.Opsona Therapeutics LtdPersonalis Inc.ProSci Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Novartis Institutes for BioMedical Research
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Journal for the Immunotherapy of Cancer (BioMed Central Ltd)
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA216951-01
Funding for this conference was made possible (in part) by CA216951-01 from the National Institutes of Heath. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 19 | 4:00PM - 8:00PM
Arrival and Registration
Room: Macdonald Foyer


Sunday, March 19 | 6:00PM - 8:00PM
Welcome Mixer
Room: Macdonald Foyer
No registration fees are used to fund alcohol served at this function.

Monday, March 20 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac/Empress Ballrooms


Monday, March 20 | 8:00AM - 9:30AM
Welcome and Keynote Session
Room: Macdonald Ballroom

Speaker 1 of 4
* Robert D. Schreiber, Washington University School of Medicine, USA

Monday, March 20 | 8:00AM - 9:30AM
Welcome and Keynote Session
Room: Macdonald Ballroom

Speaker 2 of 4
Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Mechanisms of Protective Tumor Immunity

Monday, March 20 | 8:00AM - 9:30AM
Welcome and Keynote Session
Room: Macdonald Ballroom

Speaker 3 of 4
Andreas G. Plückthun, University of Zürich, Switzerland
Future Biologics: Exploiting the Opportunities for Protein Engineering

Monday, March 20 | 8:00AM - 9:30AM
Welcome and Keynote Session
Room: Macdonald Ballroom


Coffee Break

Monday, March 20 | 9:50AM - 11:45AM
Multimodal Approaches to Immunotherapy
Room: Macdonald Ballroom

Speaker 1 of 3
* James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Blockade in Cancer Therapy: New Insights and Opportunities

Monday, March 20 | 9:50AM - 11:45AM
Multimodal Approaches to Immunotherapy
Room: Macdonald Ballroom

Speaker 2 of 3
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies

Monday, March 20 | 9:50AM - 11:45AM
Multimodal Approaches to Immunotherapy
Room: Macdonald Ballroom

Speaker 3 of 3
Nicholas P. Restifo, Lyell, USA
Genome-Scale CRISPR-Cas9 Screen Identifies Genes Essential for T Cell-Based Cancer Therapies

Monday, March 20 | 11:45AM - 5:00PM
On Own for Lunch


Monday, March 20 | 11:45AM - 1:00PM
Poster Setup
Room: Frontenac/Empress Ballrooms


Monday, March 20 | 1:00PM - 10:00PM
Poster Viewing
Room: Frontenac/Empress Ballrooms


Monday, March 20 | 2:30PM - 4:30PM
Workshop 1: Neoantigens, Vaccines and Responses
Room: Macdonald Ballroom

Speaker 1 of 6
Nicholas K. Akers, Icahn School of Medicine at Mount Sinai, USA
Modeling Tumor Immuno-Dynamics to Predict Patient Survival & Immunotherapy Efficacy

Monday, March 20 | 2:30PM - 4:30PM
Workshop 1: Neoantigens, Vaccines and Responses
Room: Macdonald Ballroom

Speaker 2 of 6
Govinda Sharma, British Columbia Cancer Agency, Canada
A Novel High-Throughput Screening Approach for the Detection of Cytotoxic T-Cell Receptor Epitopes

Monday, March 20 | 2:30PM - 4:30PM
Workshop 1: Neoantigens, Vaccines and Responses
Room: Macdonald Ballroom

Speaker 3 of 6
Sanja Stevanovic, NCI, National Institutes of Health, USA
Landscape of Immunogenic Tumor Antigens in Successful Immunotherapy of Virally-Induced Epithelial Cancer

Monday, March 20 | 2:30PM - 4:30PM
Workshop 1: Neoantigens, Vaccines and Responses
Room: Macdonald Ballroom

Speaker 4 of 6
Alice Tzeng, Cleveland Clinic Lerner College of Medicine, USA
Temporally Programmed CD8alpha+ DC Activation Enhances Combination Cancer Immunotherapy

Monday, March 20 | 2:30PM - 4:30PM
Workshop 1: Neoantigens, Vaccines and Responses
Room: Macdonald Ballroom

Speaker 5 of 6
Aileen Li, Harvard University, USA
Mesoporous Silica (MPS) Vaccine to Enhance Anti-Tumor Immunity

Monday, March 20 | 2:30PM - 4:30PM
Workshop 1: Neoantigens, Vaccines and Responses
Room: Macdonald Ballroom

Speaker 6 of 6
* Jay A. Berzofsky, NCI, National Institutes of Health, USA
Translation of Cancer Vaccines from Mice to Human Clinical Trials

Monday, March 20 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Monday, March 20 | 5:00PM - 7:15PM
Immunosuppressive Cells in the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 1 of 5
* Glenn Dranoff, Novartis Institutes for BioMedical Research, USA

Monday, March 20 | 5:00PM - 7:15PM
Immunosuppressive Cells in the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 2 of 5
Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Tregs in Cancer Immunity

Monday, March 20 | 5:00PM - 7:15PM
Immunosuppressive Cells in the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 3 of 5
Vincenzo Bronte, University of Verona, Italy
Role of Myeloid-Derived Suppressor Cells in Tumor Immunity

Monday, March 20 | 5:00PM - 7:15PM
Immunosuppressive Cells in the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 4 of 5
Alberto Mantovani, Humanitas University, Italy
Role of Macrophages in Tumor Immunity

Monday, March 20 | 5:00PM - 7:15PM
Immunosuppressive Cells in the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 5 of 5
Garry P. Nolan, Stanford University, USA
System-Wide Order, from Disorder, at the Cancer-Immune Interface

Monday, March 20 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Frontenac/Empress Ballrooms
No registration fees are used to fund alcohol served at this function.

Monday, March 20 | 7:30PM - 10:00PM
Poster Session 1
Room: Frontenac/Empress Ballrooms


Tuesday, March 21 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac/Empress Ballrooms


Tuesday, March 21 | 8:00AM - 11:15AM
Cancer Immunotherapy: Targeting Immune Checkpoints
Room: Macdonald Ballroom

Speaker 1 of 7
* Ira Mellman, Genentech, Inc., USA
PD-1/PD-L1

Tuesday, March 21 | 8:00AM - 11:15AM
Cancer Immunotherapy: Targeting Immune Checkpoints
Room: Macdonald Ballroom

Speaker 2 of 7
Riccardo Mezzadra, NKI-AvL, Netherlands
Short Talk: Identification of CMTM6 and CMTM4 as PD-L1 Protein Regulators

Tuesday, March 21 | 8:00AM - 11:15AM
Cancer Immunotherapy: Targeting Immune Checkpoints
Room: Macdonald Ballroom

Speaker 3 of 7
Andrew D. Weinberg, Earle A. Chiles Research Institute/Oregon Health & Science University, USA
OX40 Agonists: Past, Present and Future

Tuesday, March 21 | 8:00AM - 11:15AM
Cancer Immunotherapy: Targeting Immune Checkpoints
Room: Macdonald Ballroom


Coffee Break

Tuesday, March 21 | 8:00AM - 11:15AM
Cancer Immunotherapy: Targeting Immune Checkpoints
Room: Macdonald Ballroom

Speaker 5 of 7
Ana Carrizosa Anderson, Harvard Medical School, USA
Targeting Tim-3 in Cancer

Tuesday, March 21 | 8:00AM - 11:15AM
Cancer Immunotherapy: Targeting Immune Checkpoints
Room: Macdonald Ballroom

Speaker 6 of 7
Randolph J. Noelle, Dartmouth College, USA
Targeting the VISTA Pathway in Oncology

Tuesday, March 21 | 8:00AM - 11:15AM
Cancer Immunotherapy: Targeting Immune Checkpoints
Room: Macdonald Ballroom

Speaker 7 of 7
Vinidhra Mani, Harvard Medical School, USA
Short Talk: Visualizing the Mechanistic Basis of Checkpoint Blockade Therapy in Cancer

Tuesday, March 21 | 11:15AM - 5:00PM
On Own for Lunch


Tuesday, March 21 | 11:15AM - 1:00PM
Poster Setup
Room: Frontenac/Empress Ballrooms


Tuesday, March 21 | 1:00PM - 10:00PM
Poster Viewing
Room: Frontenac/Empress Ballrooms


Tuesday, March 21 | 2:30PM - 4:30PM
Workshop 2: Cellular Engineering and Therapy
Room: Macdonald Ballroom

Speaker 1 of 7
* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA

Tuesday, March 21 | 2:30PM - 4:30PM
Workshop 2: Cellular Engineering and Therapy
Room: Macdonald Ballroom

Speaker 2 of 7
Mauro Castellarin, University of Pennsylvania, USA
A Comparison of Affinity-Tuned Her2 CARs Using a New Mouse Model for On-Target Off-Tumor CAR T Cell Cytotoxicity

Tuesday, March 21 | 2:30PM - 4:30PM
Workshop 2: Cellular Engineering and Therapy
Room: Macdonald Ballroom

Speaker 3 of 7
Ashwini Balakrishnan, Fred Hutchinson Cancer Research Institute, USA
Designed Ankyrin Repeat Proteins (DARPins) as Recognition Motifs in Chimeric Antigen Receptors

Tuesday, March 21 | 2:30PM - 4:30PM
Workshop 2: Cellular Engineering and Therapy
Room: Macdonald Ballroom

Speaker 4 of 7
Kristin Anderson, University of Washington, USA
Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer

Tuesday, March 21 | 2:30PM - 4:30PM
Workshop 2: Cellular Engineering and Therapy
Room: Macdonald Ballroom

Speaker 5 of 7
Stefanie Bailey, Medical University of South Carolina, USA
CD26high T Cells have a Natural Capacity to Migrate and Persist in Multiple Tumor Models

Tuesday, March 21 | 2:30PM - 4:30PM
Workshop 2: Cellular Engineering and Therapy
Room: Macdonald Ballroom

Speaker 6 of 7
Natalie Ann Vandeven, University of Washington, USA
Novel Platform for Identifying Rare Antigen-Specific CD4 T Cells in Merkel Cell Carcinoma patients

Tuesday, March 21 | 2:30PM - 4:30PM
Workshop 2: Cellular Engineering and Therapy
Room: Macdonald Ballroom

Speaker 7 of 7
Debattama Sen, Massachusetts General Hospital, USA
The Epigenetic Landscape of T Cell Exhaustion

Tuesday, March 21 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Tuesday, March 21 | 5:00PM - 7:00PM
Cancer Immunotherapy: Combinatorial Approaches
Room: Macdonald Ballroom

Speaker 1 of 4
* Robert D. Schreiber, Washington University School of Medicine, USA
Personalized Cancer Vaccines

Tuesday, March 21 | 5:00PM - 7:00PM
Cancer Immunotherapy: Combinatorial Approaches
Room: Macdonald Ballroom

Speaker 2 of 4
Sandra Demaria, Weill Cornell Medical College, USA
Radiotherapy Needs to Go Viral to Increase Responses to Checkpoint Inhibitors


Tuesday, March 21 | 5:00PM - 7:00PM
Cancer Immunotherapy: Combinatorial Approaches
Room: Macdonald Ballroom

Speaker 3 of 4
Antoni Ribas, University of California, Los Angeles, USA
Overcoming Resistance to PD-1 Blockade Therapy

Tuesday, March 21 | 5:00PM - 7:00PM
Cancer Immunotherapy: Combinatorial Approaches
Room: Macdonald Ballroom

Speaker 4 of 4
Alyssa K. Kosmides, Johns Hopkins University, USA
Short Talk: Immunoswitch Particles: A New Approach to Cancer Immunotherapy

Tuesday, March 21 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac/Empress Ballrooms
No registration fees are used to fund alcohol served at this function.

Tuesday, March 21 | 7:30PM - 10:00PM
Poster Session 2
Room: Frontenac/Empress Ballrooms


Wednesday, March 22 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac/Empress Ballrooms


Wednesday, March 22 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Room: Macdonald Ballroom

Speaker 1 of 7
* Elizabeth M. Jaffee, Johns Hopkins University, USA
Vaccine-Based Combinatorial Immunotherapy Can Convert Pancreatic Cancers into Immunologic Diseases

Wednesday, March 22 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Room: Macdonald Ballroom

Speaker 2 of 7
Cornelia Liu Trimble, Johns Hopkins University School of Medicine, USA
High-Dimensional Analyses of the Mucosal Microenvironment in Precancerous, Intraepithelial Cervical HPV Disease

Wednesday, March 22 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Room: Macdonald Ballroom


Coffee Break

Wednesday, March 22 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Room: Macdonald Ballroom

Speaker 4 of 7
Catherine J. Wu, Dana-Farber Cancer Institute, USA
Developing and Improving Personalized Neoantigen-Targeting Cancer Vaccines

Wednesday, March 22 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Room: Macdonald Ballroom

Speaker 5 of 7
Ugur Sahin, BioNTech AG, Germany
Individualizing Cancer Treatment by mRNA Therapies

Wednesday, March 22 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Room: Macdonald Ballroom

Speaker 6 of 7
Danielle M. Talbot, Celgene, USA
Short Talk: Subclinical Irradiation-Induced Neoantigens Enhance Immunotherapy of Cancers with Low Mutational Loads

Wednesday, March 22 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Room: Macdonald Ballroom

Speaker 7 of 7
Amanda Lulu, University of Virginia, USA
Short Talk: Pre-Existing Immune Memory in Healthy Donors to Cancer-Associated Phosphopeptides

Wednesday, March 22 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, March 22 | 11:15AM - 1:00PM
Poster Setup
Room: Frontenac/Empress Ballrooms


Wednesday, March 22 | 1:00PM - 10:00PM
Poster Viewing
Room: Frontenac/Empress Ballrooms


Wednesday, March 22 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Wednesday, March 22 | 5:00PM - 7:00PM
Inflammation and the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 1 of 4
* Michael Karin, University of California, San Diego, USA
Immune Regulation of Liver Cancer: Chronic Hepatitis Promotes HCC Development by Dismantling Cancer Immunosurveillance

Wednesday, March 22 | 5:00PM - 7:00PM
Inflammation and the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 2 of 4
Shannon J. Turley, Genentech, Inc., USA
Leukocyte Function and Positioning in Diverse Stromal Niches

Wednesday, March 22 | 5:00PM - 7:00PM
Inflammation and the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 3 of 4
Thomas Gajewski, University of Chicago, USA
Tumor-Intrinsic Mediators of T Cell-Inflamed Versus Non-Inflamed Tumor Microenvironment

Wednesday, March 22 | 5:00PM - 7:00PM
Inflammation and the Tumor Microenvironment
Room: Macdonald Ballroom

Speaker 4 of 4
Evan W. Newell, Fred Hutchinson Cancer Research Center, USA
Short Talk: Deep Profiling of Human Hepatocellular Carcinoma Immune Infiltrates: Involvement of CD103+ Resident Memory-Like T and NK Cells

Wednesday, March 22 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac/Empress Ballrooms
No registration fees are used to fund alcohol served at this function.

Wednesday, March 22 | 7:30PM - 10:00PM
Poster Session 3
Room: Frontenac/Empress Ballrooms


Thursday, March 23 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac/Empress Ballrooms


Thursday, March 23 | 7:30AM - 8:00AM
Poster Setup
Room: Frontenac/Empress Ballrooms


Thursday, March 23 | 8:00AM - 5:00PM
Poster Viewing
Room: Frontenac/Empress Ballrooms


Thursday, March 23 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cellular Engineering
Room: Macdonald Ballroom

Speaker 1 of 7
* Philip D. Greenberg, University of Washington, USA
Adoptive T Cell Therapy with TCR-Engineered T Cells

Thursday, March 23 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cellular Engineering
Room: Macdonald Ballroom

Speaker 2 of 7
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
Targeting CARs to the TRAC Locus Enhances T Cell Potency

Thursday, March 23 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cellular Engineering
Room: Macdonald Ballroom


Coffee Break

Thursday, March 23 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cellular Engineering
Room: Macdonald Ballroom

Speaker 4 of 7
Carl H. June, University of Pennsylvania, USA
CAR-T Therapy of ALL

Thursday, March 23 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cellular Engineering
Room: Macdonald Ballroom

Speaker 5 of 7
Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
CAR-T Cells for Hematopoietic and Solid Tumors

Thursday, March 23 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cellular Engineering
Room: Macdonald Ballroom

Speaker 6 of 7
Agne Taraseviciute, Seattle Children's Research Institute, USA
Short Talk: A Non-Human Primate Model That Recapitulates B Cell-directed Chimeric Antigen Receptor (CAR) T cell-mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity

Thursday, March 23 | 8:00AM - 11:15AM
Cancer Immunotherapy: Cellular Engineering
Room: Macdonald Ballroom

Speaker 7 of 7
Daniel T. Harris, University of Illinois, USA
Short Talk: A Comparison of T Cell Sensitivity using TCR and CAR Constructs with the Same pepMHC Binding Domain

Thursday, March 23 | 11:15AM - 12:15PM
Lunch
Room: Frontenac/Empress Ballrooms


Thursday, March 23 | 12:00PM - 2:30PM
Poster Session 4
Room: Frontenac/Empress Ballrooms


Thursday, March 23 | 2:30PM - 4:30PM
Workshop 3: A Deeper Dive into Cancer Immunotherapy
Room: Macdonald Ballroom

Speaker 1 of 7
* Evan W. Newell, Fred Hutchinson Cancer Research Center, USA

Thursday, March 23 | 2:30PM - 4:30PM
Workshop 3: A Deeper Dive into Cancer Immunotherapy
Room: Macdonald Ballroom

Speaker 2 of 7
Brian Christopher Miller, Dana-Farber Cancer Institute, USA
Dissecting Mechanisms of anti-PD-1 Therapy with Massively Parallel Single-Cell RNA-Sequencing

Thursday, March 23 | 2:30PM - 4:30PM
Workshop 3: A Deeper Dive into Cancer Immunotherapy
Room: Macdonald Ballroom

Speaker 3 of 7
Wouter Scheper, Netherlands Cancer Institute, Netherlands
Unbiased Single-Cell TCR Analysis Reveals Infrequent Tumor-Reactivity Among T Cells Infiltrating Human Cancers

Thursday, March 23 | 2:30PM - 4:30PM
Workshop 3: A Deeper Dive into Cancer Immunotherapy
Room: Macdonald Ballroom

Speaker 4 of 7
Spencer C. Wei, Spotlight Therapeutics, USA
Distinct Cellular Mechanisms Mediate Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Thursday, March 23 | 2:30PM - 4:30PM
Workshop 3: A Deeper Dive into Cancer Immunotherapy
Room: Macdonald Ballroom

Speaker 5 of 7
Yonit Lavin, Mount Sinai School of Medicine, USA
High Dimensional Analysis of Untreated Early Lung Cancer Lesions Reveals Novel Myeloid Immune Responses to Tumor

Thursday, March 23 | 2:30PM - 4:30PM
Workshop 3: A Deeper Dive into Cancer Immunotherapy
Room: Macdonald Ballroom

Speaker 6 of 7
Ken-Edwin Aryee, University of Massachusetts Medical School, USA
Humanized Mouse; A Model for Understanding Tumor-Immune System Interactions

Thursday, March 23 | 2:30PM - 4:30PM
Workshop 3: A Deeper Dive into Cancer Immunotherapy
Room: Macdonald Ballroom

Speaker 7 of 7
Aya Ludin Tal, Harvard University, USA
The Zebrafish as a Model for T Cell Recruitment to Melanoma

Thursday, March 23 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Thursday, March 23 | 5:00PM - 6:45PM
Nex-Gen Technologies
Room: Macdonald Ballroom

Speaker 1 of 3
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Combining Lymph Node Targeting Cancer Vaccines with Systemic Immunotherapy to Recruit an Innate and Adaptive Attack Against Established Tumors

Thursday, March 23 | 5:00PM - 6:45PM
Nex-Gen Technologies
Room: Macdonald Ballroom

Speaker 2 of 3
* Lisa M. Coussens, Oregon Health & Science University, USA
Monitoring Inflammation in Cancer by Multi-Plex in situ Imaging

Thursday, March 23 | 5:00PM - 6:45PM
Nex-Gen Technologies
Room: Macdonald Ballroom

Speaker 3 of 3
Jim R. Heath, California Institute of Technology, USA
Micro- and Nanotechnologies for Personalizing Cancer Immunotherapy

Thursday, March 23 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Macdonald Ballroom


Thursday, March 23 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac/Empress Ballrooms
No registration fees are used to fund alcohol served at this function.

Thursday, March 23 | 8:00PM - 11:00PM
Entertainment
Room: Frontenac
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, March 23 | 8:00PM - 11:00PM
Cash Bar
Room: Frontenac


Friday, March 24 | 10:25AM - 10:25AM
Departure


*Session Chair.